{"id":"W2309983655","doi":"10.1007/s10637-016-0335-x","title":"Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancer","year":2016,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute; National Institutes of Health","keywords":"Veliparib; Cyclophosphamide; PARP inhibitor; Medicine; Triple-negative breast cancer; Nitrogen mustard; Internal medicine; Oncology; Breast cancer; Chemotherapy; Metastatic breast cancer; Pharmacology; Cancer; Poly ADP ribose polymerase; Biology; Polymerase","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001453006,0.001624491,0.003133881,0.0003629838,0.0004370793,0.001467146,0.001025605,0.001531784,0.008649279],"category_scores_gemma":[0.001831486,0.0008838064,0.001647105,0.0004771647,0.001420369,0.001160739,0.0005430019,0.004484181,0.001348142],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001139881,"about_ca_system_score_gemma":0.00145967,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001489105,"about_ca_topic_score_gemma":0.003701757,"domain_scores_codex":[0.9993941,0.0003226557,0.00002793618,0.00012266,0.00003047046,0.000102267],"domain_scores_gemma":[0.9989441,0.0003094677,0.0001857232,0.0001104339,0.00004870674,0.0004015133],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9793842,0.005052014,0.0005259374,0.0002632641,0.0007461975,0.00003455316,0.00003798645,0.0004922466,0.001607927,0.0001432824,0.0008846825,0.0108277],"study_design_scores_gemma":[0.967272,0.03040057,0.0007364611,0.00001272813,0.0002570269,0.00002700282,0.00001958701,0.0003478615,0.0001807484,0.0001628832,0.0005745239,0.000008655544],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9804084,0.00454415,0.001148102,0.001520571,0.001194341,0.004668663,0.001952357,0.0001784604,0.004384933],"genre_scores_gemma":[0.9793968,0.002997877,0.001827256,0.002067247,0.0006384556,0.004459908,0.002229126,0.00005619392,0.006327215],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008649279,"threshold_uncertainty_score":0.02893478,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01259685493353731,"score_gpt":0.2914200369288869,"score_spread":0.2788231819953496,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}